Screening and application of targeted biological peptide for inhibiting autoimmune inflammatory response of eyes

Abstract

The invention provides a targeted biological peptide for inhibiting autoimmune inflammatory response of eyes and application of the targeted biological peptide. The invention also relates to a preparation method and application of the polypeptide and a pharmaceutical composition containing the polypeptide. The polypeptide disclosed by the invention has various advantages, such as small molecular weight, low production cost, good water solubility, small immunogenicity, low toxic and side effects, strong tissue penetrability and the like; moreover, researches on two models, namely EAE and EAU, show that the biological peptide has remarkable effects of immunoregulation, inflammation resistance and visual function improvement.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a targeted biopeptide for inhibiting ocular autoimmune inflammatory response and application thereof. Background technique [0002] With the improvement of the sanitation environment, the proportion of infectious diseases in ocular inflammatory diseases has gradually decreased, while the incidence of autoimmune eye diseases has increased year by year. [0003] Autoimmune eye diseases can be primary diseases of the eye, such as Koyanagi-Harada disease, white spot syndrome, etc., but are more often seen as ocular manifestations of systemic autoimmune diseases, such as neuromyelitis optica (NMO) and Multiple sclerosis (multiple sclerosis, MS). Ocular autoimmune diseases can affect multiple parts including the ocular surface, inner eye, and ocular appendages, among which the uvea and optic nerve are most likely to be involved. [0004] Due to their recurrent characteristics, ...

AI Technical Summary

Problems solved by technology

[0008] However, most of these emerging targeted therapy drugs are biomacromolecules, which have the following disadvantages in specific applications: i) large molecular weight, complicated in vitro synthesis methods, cumbersome recombinant expression and purification processes in the preparation process, and residual endotoxins. Higher production cost; ii) Strong antigenicity, easy to induce host immune response and aggravate immune disorders; iii) Easy to lose biological activity due to changes in protein conformation and modification groups; iv) Due to the special anatomical structure of the eyeball These macromolecular compounds are often difficult to pass through the blood-ocular barrier and blood-optic nerve barrier, and many of them require intravitreal injection or intrathecal injection, which makes it difficult to popularize and apply clinically.

[0009] In general, at present, in the field of targeted therapy for autoimmune uveitis and optic neuritis, there is still a lack of a treatment method with the characteristics of definite curative effect, low toxicity, small side effects, and high cost performance.

Images